By a GenomeWeb staff reporter
NEW YORK (GenomeWeb News) – Agilent Technologies this week said that it expects its acquisition of Varian to close in either late April or early May. The $1.5 billion deal was signed last June, but had been held up by regulatory reviews in the EU and US.
Registering provides access to this and other free content.
Already have an account?Login Now.
The US Food and Drug Administration has approved Kite Pharmaceuticals' CAR T-cell therapy for large B-cell lymphomas, the New York Times reports.
Kaiser Health News reports that gene therapies could cost more than a million dollars.
Worcester Polytechnic Institute researchers have received a grant to combine biology and computer science for high school students.
In Nature this week: variants associated with obsessive-compulsive disorder, review of key CRISPR enzymes, and more.